These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688 [TBL] [Abstract][Full Text] [Related]
5. Association between clinicopathologic characteristics and BRAF Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596 [TBL] [Abstract][Full Text] [Related]
6. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA. Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272 [TBL] [Abstract][Full Text] [Related]
7. BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy. Wang CJ; Zhu T; Zhao CZ; Cui H; Wang D; Zhao ZJ; Huang XT; Li HL; Liu FF; Zhang R; Li ZG; Cui L Pediatr Blood Cancer; 2024 Sep; 71(9):e31099. PubMed ID: 38845144 [TBL] [Abstract][Full Text] [Related]
8. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis]. Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453 [TBL] [Abstract][Full Text] [Related]
9. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. Donadieu J; Larabi IA; Tardieu M; Visser J; Hutter C; Sieni E; Kabbara N; Barkaoui M; Miron J; Chalard F; Milne P; Haroche J; Cohen F; Hélias-Rodzewicz Z; Simon N; Jehanne M; Kolenova A; Pagnier A; Aladjidi N; Schneider P; Plat G; Lutun A; Sonntagbauer A; Lehrnbecher T; Ferster A; Efremova V; Ahlmann M; Blanc L; Nicholson J; Lambilliote A; Boudiaf H; Lissat A; Svojgr K; Bernard F; Elitzur S; Golan M; Evseev D; Maschan M; Idbaih A; Slater O; Minkov M; Taly V; Collin M; Alvarez JC; Emile JF; Héritier S J Clin Oncol; 2019 Nov; 37(31):2857-2865. PubMed ID: 31513482 [TBL] [Abstract][Full Text] [Related]
16. Wang CJ; Cui L; Ma HH; Wang D; Zhang L; Lian HY; Li WJ; Zhang Q; Wang TY; Li ZG; Zhang R Mol Cancer Ther; 2021 Jul; 20(7):1316-1323. PubMed ID: 33879554 [TBL] [Abstract][Full Text] [Related]
17. High Prevalence of Liu X; Zhang Y; Zhou CX Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679 [TBL] [Abstract][Full Text] [Related]
18. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Roden AC; Hu X; Kip S; Parrilla Castellar ER; Rumilla KM; Vrana JA; Vassallo R; Ryu JH; Yi ES Am J Surg Pathol; 2014 Apr; 38(4):548-51. PubMed ID: 24625419 [TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival. Bhatia P; Singh M; Sharma M; Sharma A; Kakkar N; Radhika S; Trehan A; Bansal D Blood Cells Mol Dis; 2020 May; 82():102356. PubMed ID: 32171112 [TBL] [Abstract][Full Text] [Related]